Testosterone Enanthate: Switching From or To Other Drugs in Class

How Testosterone Enanthate Works

Testosterone enanthate is an esterified form of testosterone designed for intramuscular or subcutaneous depot injection. Once injected, serum esterase enzymes cleave the enanthate ester from the parent testosterone molecule, releasing free testosterone into circulation over approximately 7 to 10 days [1].

Mechanism at the Receptor Level

Free testosterone exerts its effects through two primary pathways. It binds directly to the androgen receptor (AR), a nuclear receptor that, once activated, translocates to the nucleus and modulates gene transcription. Separately, a portion of circulating testosterone is converted to estradiol via the aromatase enzyme (CYP19A1) in adipose tissue, muscle, and the liver, producing estrogenic effects on bone density and cardiovascular tissue [2].

A smaller fraction is reduced to dihydrotestosterone (DHT) by 5-alpha reductase, a metabolite with roughly five times the AR-binding affinity of testosterone itself. DHT drives androgenic effects in hair follicles and the prostate [3]. Understanding this metabolic branching matters for switching decisions: some formulations deliver more stable free-testosterone curves, which in turn produce more predictable estradiol and DHT levels downstream.

Why the Enanthate Ester Specifically

The enanthate ester has eight carbon atoms in its side chain, giving testosterone enanthate a log P (octanol-water partition coefficient) that enables slow, sustained release from the oil-based depot. This pharmacokinetic profile is nearly identical to testosterone cypionate, which carries a cyclohexanecarboxylate ester of similar lipophilicity. The Endocrine Society's 2018 clinical practice guideline states that testosterone enanthate and cypionate are "therapeutically equivalent" and may be used interchangeably at the same dose [4].

Peak serum testosterone after a 200 mg IM injection of enanthate typically occurs at 24 to 72 hours post-injection, then declines with a half-life of approximately 4.5 days [1]. At a standard weekly dosing interval, trough levels stabilize after roughly three to four injection cycles, or about 21 to 28 days.

Pharmacokinetic Basis for Switching Decisions

Before changing any testosterone formulation, a prescriber must account for the drug's effective half-life, the time to achieve a new steady state, and the overlap window during which two formulations may be simultaneously active. Getting this wrong produces either a gap with symptomatic hypogonadism or a prolonged supraphysiologic peak.

Half-Lives Across the Testosterone Drug Class

| Formulation | Route | Approximate Half-Life | Time to New Steady State | |---|---|---|---| | Testosterone enanthate | IM / SubQ | ~4.5 days | ~21 days | | Testosterone cypionate | IM / SubQ | ~8 days | ~42 days | | Testosterone undecanoate (Aveed) | IM | ~20.9 days | ~12 weeks | | Testosterone undecanoate (Jatenzo) | Oral | ~4 hours | ~2 days | | Testosterone gel 1% (AndroGel) | Transdermal | ~70 minutes (once removed) | ~1 to 2 days | | Testosterone pellets (Testopel) | SubQ implant | ~85 to 120 days | N/A (single-load) |

Data compiled from FDA prescribing information for each product [5][6][7].

Steady-State Testosterone and the T-Trials Benchmark

The T-Trials (N=788 men aged 65 or older with confirmed hypogonadism, NEJM 2016) targeted a serum total testosterone of 500 to 1,000 ng/dL using testosterone gel. Participants who reached that target window showed statistically significant improvements in sexual desire, erectile function, and self-reported vitality compared with placebo [8]. That 500 to 1,000 ng/dL window is widely used as a clinical benchmark when transitioning between formulations, with trough levels checked 2 to 4 weeks after reaching a new steady state.

The Endocrine Society guideline specifies: "We recommend measuring testosterone levels to ensure that they are in the mid-normal range (400 to 700 ng/dL at trough) for the chosen formulation" [4]. Trough timing differs by formulation: for enanthate dosed weekly, trough is drawn just before the next injection; for transdermal gels, any morning draw after at least one week of use suffices.

Switching FROM Testosterone Enanthate

To Testosterone Cypionate (The Simplest Switch)

Enanthate and cypionate share nearly identical pharmacokinetics. The FDA labels for both products list the same indications, the same general dosing range of 50 to 400 mg every 2 to 4 weeks for hypogonadism, and comparable peak-to-trough ratios at equivalent doses [5][6].

In practice, a 1:1 milligram-for-milligram substitution on the same schedule is appropriate. A patient on 100 mg enanthate weekly simply begins 100 mg cypionate on the next scheduled injection day. No washout period is needed. Recheck total testosterone at trough (just before injection four or five) to confirm the target range.

One practical reason patients switch: supply. Enanthate has historically faced periodic shortage cycles in U.S. Compounding pharmacies, whereas pharmaceutical-grade testosterone cypionate (Depo-Testosterone, Pfizer) has more consistent availability [9].

To Testosterone Undecanoate Injection (Aveed)

Aveed is dosed as 750 mg IM at baseline, then at week 4, then every 10 weeks thereafter. Its long half-life of approximately 20.9 days means it takes 12 or more weeks to reach a true steady state [7].

The transition plan: give the first Aveed dose on the day the next enanthate injection would have been due. This prevents a hypogonadal gap. Because Aveed's peak after dose one is lower than its eventual steady-state peak, patients may notice mild hypogonadal symptoms during weeks 6 to 10 of the loading phase. Warn patients explicitly. Recheck testosterone at week 14 (trough, just before the third maintenance injection).

Aveed carries an FDA boxed warning for pulmonary oil microembolism (POME) and anaphylaxis, requiring a 30-minute observation period in a healthcare setting after each injection [7]. This safety consideration sometimes drives the reverse switch, from Aveed back to enanthate, for patients who prefer self-administration.

To Oral Testosterone Undecanoate (Jatenzo)

Jatenzo (testosterone undecanoate 158, 198, or 237 mg oral capsules) is absorbed via the intestinal lymphatic system and has a plasma half-life of roughly 4 hours, requiring twice-daily dosing with food [10].

Because enanthate's depot clears within 21 days of the last injection, a prescriber can start Jatenzo the day after the last enanthate injection with minimal overlap risk. The starting dose is 237 mg twice daily with the morning and evening meals, titrated based on a testosterone level drawn 6 hours after the morning dose at 3 to 4 weeks [10]. Jatenzo carries an FDA warning for blood pressure increases, averaging 3 to 5 mmHg systolic in clinical trials, so blood pressure should be checked at the 4-week visit [10].

To Testosterone Gel 1% (AndroGel or Generic)

Transdermal testosterone gels reach steady state within 24 to 48 hours of first application because they deliver daily doses without depot accumulation. The main challenge is dose equivalence. A patient on 100 mg enanthate weekly is receiving roughly 14.3 mg of testosterone base per day (before ester weight adjustment). Gel formulations deliver testosterone at an absorption efficiency of approximately 10%, meaning a nominally labeled 50 mg/day gel packet delivers roughly 5 mg of absorbed testosterone [11].

Starting gel the day after the last enanthate injection is acceptable. Clinicians typically start at 50 mg/day (one packet) and recheck morning testosterone after 14 days, titrating to 75 or 100 mg/day if trough levels remain below 400 ng/dL. The NEJM trial literature, including data from the T-Trials, used this titration approach [8].

To Subcutaneous Testosterone Pellets (Testopel)

Testopel pellets (75 mg each) are implanted subcutaneously, typically in the buttock, and release testosterone over 3 to 6 months. The number of pellets inserted (usually 6 to 12 for men) is calibrated to body weight and baseline testosterone [12].

A patient switching from enanthate to pellets should receive the pellet implant at the time the next enanthate injection would be due, to avoid overlap-induced supraphysiologic peaks. Because pellet release is front-loaded, testosterone levels peak in weeks 4 to 8 and decline gradually. Recheck at week 6 to confirm peak levels remain below 1,100 ng/dL, and again at month 4 to assess for trough hypogonadism before re-implantation.

Switching TO Testosterone Enanthate

From Testosterone Cypionate

This is the mirror image of the enanthate-to-cypionate switch. Use a 1:1 milligram substitution on the same day the next cypionate injection would be due. No washout, no dose adjustment at initiation.

From Testosterone Undecanoate Injection (Aveed)

Aveed's 20.9-day half-life means that after the last Aveed injection, the drug contributes meaningful serum testosterone for 12 to 16 weeks [7]. Starting enanthate immediately after the last Aveed dose risks a prolonged supraphysiologic period during the first 4 to 6 weeks.

The recommended approach: wait 10 to 12 weeks after the last Aveed injection before initiating enanthate. Check total testosterone at week 10; if it has fallen below 400 ng/dL, begin enanthate at 75 to 100 mg weekly at that point. If testosterone remains above 500 ng/dL at week 10, wait another 2 weeks and recheck.

From Oral Testosterone Undecanoate (Jatenzo)

Jatenzo's 4-hour half-life means serum levels normalize within 24 hours of the last dose. A patient can receive their first enanthate injection the morning after stopping Jatenzo. Because oral and injectable testosterone have different absorption patterns, check a trough testosterone level at week 3 of enanthate to confirm adequate levels.

From Testosterone Gel

Gels reach near-zero serum levels within 24 to 48 hours of removal. The first enanthate injection can be given on the first day of stopping gel application. Given the rapid decline, patients should not miss the first injection appointment; even a 3-day delay may produce symptomatic hypogonadism.

From Subcutaneous Pellets

Pellets cannot be removed easily once implanted. If a patient needs to switch to enanthate, the clinical strategy depends on timing within the pellet cycle.

If pellets were inserted within the past 6 weeks (early, high-release phase), adding enanthate risks supraphysiologic testosterone. Hold enanthate until pellet-derived testosterone falls below 500 ng/dL, which typically requires 12 to 16 weeks from insertion.

If pellets are in the late phase (month 4 or later) and testosterone has already declined below 400 ng/dL, enanthate can be started immediately at a conservative 50 to 75 mg weekly dose with a recheck at week 3.

Monitoring Protocol After Any Formulation Switch

The following framework applies to all enanthate-related transitions and is organized by formulation pair:

Enanthate / Cypionate switches: Total testosterone (trough) at week 3 to 4. Hematocrit at week 6 to 8. No PSA recheck needed unless baseline was borderline.

Enanthate / Undecanoate injection switches: Total testosterone at week 10 to 12 (washout phase) and again at week 14 to 16 (new steady state). Hematocrit, PSA, and blood pressure at week 16.

Enanthate / Oral undecanoate switches: Testosterone at 6 hours post-morning-dose at week 3 to 4. Blood pressure at each visit for the first 3 months.

Enanthate / Gel switches: Morning total testosterone at week 2 and week 6. Check for application site transfer risk if patient has female or pediatric household contacts (FDA advisory [13]).

Enanthate / Pellet switches: Total testosterone at weeks 4 to 6 (peak check) and months 4 to 5 (trough check before re-implantation). Hematocrit at week 8.

The AUA 2018 guideline on testosterone deficiency states: "Clinicians should monitor hematocrit, and if it rises to greater than 54%, should discontinue testosterone therapy until hematocrit normalizes" [14]. This threshold applies regardless of formulation and should be checked 3 to 6 months after any switch that changes the total testosterone area-under-the-curve.

Special Populations and Switching Considerations

Older Men

The T-Trials enrolled men 65 years and older and found that maintaining testosterone in the 500 to 1,000 ng/dL range improved sexual function (primary endpoint P<0.001) and physical function (6-minute walk distance) compared with placebo [8]. Older men often tolerate weekly enanthate injections poorly due to injection site discomfort. Switching to gel or oral undecanoate may improve adherence in this group, with the trade-off of more complex dosing logistics.

Men Seeking Fertility

Exogenous testosterone of any formulation suppresses the hypothalamic-pituitary-gonadal axis, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to near-zero within 4 to 6 weeks of initiation [15]. Switching between formulations does not restore fertility. Men who require testosterone therapy but want to preserve fertility should receive gonadotropin-based therapy (human chorionic gonadotropin, FSH injections) instead, per the AUA and American Society for Reproductive Medicine guidance [16].

If a man on any testosterone formulation wants to attempt conception, testosterone must be discontinued entirely. Spermatogenesis may recover in 6 to 24 months, with longer suppression durations predicting longer recovery times [15].

Polycythemia Risk by Formulation

Injectable testosterone (enanthate, cypionate, undecanoate) produces higher peak serum levels than transdermal or oral formulations and is associated with a greater risk of secondary polycythemia. A 2021 systematic review in the Journal of Clinical Endocrinology and Metabolism found that hematocrit elevation above 50% occurred in approximately 11% of men on injectable testosterone versus 3% on transdermal testosterone [17]. Patients with baseline hematocrit above 48% may be better candidates for gel, patch, or oral formulations.

Dose Conversion Reference Table

| Switching From | Switching To | Dose Conversion | Washout Needed | |---|---|---|---| | Enanthate 100 mg/week | Cypionate 100 mg/week | 1:1 | None | | Enanthate 200 mg/2 weeks | Aveed 750 mg/10 weeks | Start Aveed on next injection day | None | | Enanthate 100 mg/week | Jatenzo 237 mg BID | Start Jatenzo day after last injection | None (24 hr) | | Enanthate 100 mg/week | AndroGel 50 mg/day | Start gel day after last injection; titrate up | None (24 hr) | | Enanthate 100 mg/week | Testopel (pellets) | Insert pellets on next injection day | None | | Aveed 750 mg/10 weeks | Enanthate 100 mg/week | Wait 10 to 12 weeks post-Aveed | 10 to 12 weeks | | Pellets (early phase) | Enanthate 75 mg/week | Wait until T <500 ng/dL | 12 to 16 weeks | | Jatenzo 237 mg BID | Enanthate 100 mg/week | First injection morning after last Jatenzo | 24 hours | | AndroGel 50 mg/day | Enanthate 100 mg/week | First injection on gel stop day | 24 to 48 hours |